P
SRPT icon

&Partners’s Sarepta Therapeutics SRPT Stock Holding History

&Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$780K Buy
43,404
+5,960
+16% +$113K ﹤0.01% 1570
2026
Q1 		$815K Sell
37,444
-75,002
-67% -$1.45M ﹤0.01% 1417
2025
Q4 		$2.23M Buy
+112,446
New +$2.37M 0.01% 811

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

&Partners's SRPT Position: Q2 2026 in Review

&Partners increased its Sarepta Therapeutics (SRPT) stake by 16% in Q2 2026, buying an estimated $113K and bringing the position to 43,404 shares worth $780K. The position accounts for ﹤0.01% of the portfolio, ranked #1570.

&Partners first reported a position in SRPT in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.23M in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • &Partners held 43,404 shares of Sarepta Therapeutics worth $780K as of Q2 2026.
  • &Partners bought 5,960 Sarepta Therapeutics shares in Q2 2026, an estimated $113K.
  • Sarepta Therapeutics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #1570 holding.
  • &Partners first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • &Partners's Sarepta Therapeutics position peaked at $2.23M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.